Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma

Leukemia and Lymphoma

Volumn 50, Issue 2, 2009, Pages 236-246

  Damgaard, Tina ^a   Knudsen, Lene M ^b   Dahl, Inger Marie S ^c,d   Gimsing, Peter ^b   Lodahl, Marianne ^a   Rasmussen, Thomas ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Anti apoptosis; CD56; Clinical factors; Multiple myeloma; Proliferation; Transcriptional regulation

Indexed keywords

CD56 ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MELPHALAN; MESSENGER RNA; PREDNISONE; THALIDOMIDE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BTBD3; TRANSCRIPTION FACTOR MMSET I; TRANSCRIPTION FACTOR MMSET II; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; APOPTOSIS; CELL PROLIFERATION; CYCLIN D1; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 61349121551     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802699332     Document Type: Article

References (43)

1. Bergsagel, P. L. and Kuehl, W. M. (2001) Chromosome translocations in multiple myeloma. Oncogene, 20, pp. 5611-5622.
2. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K. Naito, K. et al. (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol, 117, pp. 882-885.
3. Hideshima, T., Bergsagel, P. L., Kuehl, W. M. and Anderson, K. C. (2004) Advances in biology of multiple myeloma: Clinical applications. Blood, 104, pp. 607-618.
4. Mateo, G., Montalban, M. A., Vidriales, M. B., Lahuerta, J. J., Mateos, M. V. Gutierrez, N. et al. (2008) Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol, 1:26, pp. 2737-2744.
5. Ely, S. A. and Knowles, D. M. (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol, 160, pp. 1293-1299.
6. Barker, H. F., Hamilton, M. S., Ball, J., Drew, M. and Franklin, I. M. (1992) Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol, 81, pp. 331-335.
7. Drach, J., Gattringer, C. and Huber, H. (1991) Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol, 83, pp. 418-422.
8. Harada, H., Kawano, M. M., Huang, N., Harada, Y., Iwato, K. Tanabe, O. et al. (1993) Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 81, pp. 2658-2663.
9. Van Riet, I., De Waele, M., Remels, L., Lacor, P., Schots, R. and Van Camp, B. (1991) Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol, 79, pp. 421-427.
10. Dahl, I. M., Rasmussen, T., Kauric, G. and Husebekk, A. (2002) Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol, 116, pp. 273-277.
11. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N. Pineau, D. et al. (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia, 12, pp. 1977-1982.
12. Rawstron, A., Barrans, S., Blythe, D., Davies, F., English, A. Pratt, G. et al. (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol, 104, pp. 138-143.
13. Rawstron, A. C., Owen, R. G., Davies, F. E., Johnson, R. J., Jones, R. A. Richards, S. J. et al. (1997) Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage. Br J Haematol, 97, pp. 46-55.
14. Chang, H., Bartlett, E. S., Patterson, B., Chen, C. I. and Yi, Q. L. (2005) The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. Br J Haematol, 129, pp. 539-541.
15. Sahara, N. and Takeshita, A. (2004) Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens. Leuk Lymphoma, 45, pp. 61-65.
16. Hundemer, M., Klein, U., Hose, D., Raab, M. S., Cremer, F. W. Jauch, A. et al. (2007) Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant, 40, pp. 1033-1037.
17. Nguyen, C., Mattei, M. G., Mattei, J. F., Santoni, M. J., Goridis, C. and Jordan, B. R. (1986) Localization of the human NCAM gene to band q23 of chromosome 11: The third gene coding for a cell interaction molecule mapped to the distal portion of the long arm of chromosome 11. J Cell Biol, 102, pp. 711-715.
18. Gattenloehner, S., Chuvpilo, S., Langebrake, C., Reinhardt, D., Muller-Hermelink, H. K. Serfling, E. et al. (2007) Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression. Blood, 110, pp. 2027-2033.
19. Agnelli, L., Bicciato, S., Mattioli, M., Fabris, S., Intini, D. Verdelli, D. et al. (2005) Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol, 23, pp. 7296-7306.
20. Nutt, S. L., Heavey, B., Rolink, A. G. and Busslinger, M. (1999) Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature, 401, pp. 556-562.
21. Lin, P., Mahdavy, M., Zhan, F., Zhang, H. Z., Katz, R. L. and Shaughnessy, J. D. (2004) Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray. Mod Pathol, 17, pp. 1217-1222.
22. Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D. J. Sirulnik, A. et al. (2008) The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood, 111, pp. 3145-3154.
23. Rasmussen, T., Knudsen, L. M. and Johnsen, H. E. (2001) Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol, 67, pp. 296-301.
24. Keats, J. J., Reiman, T., Maxwell, C. A., Taylor, B. J., Larratt, L. M. Mant, M. J. et al. (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101, pp. 1520-1529.
25. Rasmussen, T., Knudsen, L. M., Dahl, I. M. and Johnsen, H. E. (2003) C-MAF oncogene dysregulation in multiple myeloma: Frequency and biological relevance. Leuk Lymphoma, 44, pp. 1761-1766.
26. Rasmussen, T., Jensen, L., Honore, L., Andersen, H. and Johnsen, H. E. (1999) Circulating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays. Br J Haematol, 107, pp. 818-824.
27. Rasmussen, T., Theilgaard-Monch, K., Hudlebusch, H. R., Lodahl, M., Johnsen, H. E. and Dahl, I. M. (2003) Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: Indications for different disease entities. Br J Haematol, 123, pp. 253-262.
28. Borson, N. D., Lacy, M. Q. and Wettstein, P. J. (2002) Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood, 100, pp. 4629-4639.
29. Holst, B. D., Wang, Y., Jones, F. S. and Edelman, G. M. (1997) A binding site for Pax proteins regulates expression of the gene for the neural cell adhesion molecule in the embryonic spinal cord. Proc Natl Acad Sci USA, 94, pp. 1465-1470.
30. Wildonger, J. and Mann, R. S. (2005) The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development, 132, pp. 2263-2272.
31. Lorsbach, R. B., Moore, J., Ang, S. O., Sun, W., Lenny, N. and Downing, J. R. (2004) Role of RUNX1 in adult hematopoiesis: Analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood, 103, pp. 2522-2529.
32. Andersen, M. K., Christiansen, D. H. and Pedersen-Bjergaard, J. (2005) Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia, 19, pp. 197-200.
33. Kozu, T., Fukuyama, T., Yamami, T., Akagi, K. and Kaneko, Y. (2005) MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer, 43, pp. 45-53.
34. Bernardin, F. and Friedman, A. D. (2002) AML1 stimulates G1 to S progression via its transactivation domain. Oncogene, 21, pp. 3247-3252.
35. Choi, S. J., Oba, T., Callander, N. S., Jelinek, D. F. and Roodman, G. D. (2003) AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma. Blood, 101, pp. 3778-3783.
36. Chesi, M., Nardini, E., Lim, R. S., Smith, K. D., Kuehl, W. M. and Bergsagel, P. L. (1998) The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood, 92, pp. 3025-3034.
37. Rasmussen, T., Hudlebusch, H. R., Knudsen, L. M. and Johnsen, H. E. (2002) FGFR3 dysregulation in multiple myeloma: Frequency and prognostic relevance. Br J Haematol, 117, pp. 626-628.
38. De Greef, C., Van Riet, I., Bakkus, M. H. and Van Camp, B. (1998) Differential gene expression of the neural cell adhesion molecule (N-CAM) in a panel of multiple myeloma cell lines. Leukemia, 12, pp. 86-93.
39. Kraj, M., Sokolowska, U., Kopec-Szlezak, J., Poglod, R., Kruk, B. Wozniak, J. et al. (2008) Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma, 49, pp. 298-305.
40. Ouyang, W., Ma, Q., Li, J., Zhang, D., Liu, Z. G. Rustgi, A. K. et al. (2005) Cyclin D1 induction through IκB kinase beta/nuclear factor-κB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes. Cancer Res, 65, pp. 9287-9293.
41. Bergsagel, P. L., Kuehl, W. M., Zhan, F., Sawyer, J., Barlogie, B. and Shaughnessy, J. J. (2005) Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood, 106, pp. 296-303.
42. Inaba, T., Matsushime, H., Valentine, M., Roussel, M. F., Sherr, C. J. and Look, A. T. (1992) Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics, 13, pp. 565-574.
43. Soverini, S., Cavo, M., Cellini, C., Terragna, C., Zamagni, E. Ruggeri, D. et al. (2003) Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood, 102, pp. 1588-1594.